AU2095599A - Human genes and gene expression products i - Google Patents

Human genes and gene expression products i

Info

Publication number
AU2095599A
AU2095599A AU20955/99A AU2095599A AU2095599A AU 2095599 A AU2095599 A AU 2095599A AU 20955/99 A AU20955/99 A AU 20955/99A AU 2095599 A AU2095599 A AU 2095599A AU 2095599 A AU2095599 A AU 2095599A
Authority
AU
Australia
Prior art keywords
gene expression
expression products
human genes
genes
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20955/99A
Other languages
English (en)
Inventor
Radomir Crkvenjakov
Mark Dickson
Radoje Drmanac
Snezana Drmanac
Jaime Escobedo
Pablo Dominguez Garcia
Klaus Giese
Michael A. Innis
Altaf Kassam
Giulia C. Kennedy
Ivan Labat
George Lamson
Dena Leshkowitz
David Pot
Filippo Randazzo
Christoph Reinhard
Julie Sudduth-Klinger
Lewis T. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Hyseq Inc
Original Assignee
Hyseq Inc
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyseq Inc, Chiron Corp filed Critical Hyseq Inc
Publication of AU2095599A publication Critical patent/AU2095599A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU20955/99A 1997-12-23 1998-12-25 Human genes and gene expression products i Abandoned AU2095599A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US6875597P 1997-12-23 1997-12-23
US60068755 1997-12-23
US8066498P 1998-04-03 1998-04-03
US60080664 1998-04-03
US10523498P 1998-10-21 1998-10-21
US60105234 1998-10-21
US10587798P 1998-10-27 1998-10-27
US60105877 1998-10-27
US21747198A 1998-12-21 1998-12-21
US09217471 1998-12-21
PCT/US1998/027610 WO1999033982A2 (en) 1997-12-23 1998-12-22 Human genes and gene expression products i

Publications (1)

Publication Number Publication Date
AU2095599A true AU2095599A (en) 1999-07-19

Family

ID=27535805

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20955/99A Abandoned AU2095599A (en) 1997-12-23 1998-12-25 Human genes and gene expression products i

Country Status (4)

Country Link
EP (1) EP1190058A2 (de)
JP (1) JP2002500010A (de)
AU (1) AU2095599A (de)
WO (1) WO1999033982A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617438B1 (en) * 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6733990B1 (en) 1999-08-03 2004-05-11 Millennium Pharmaceuticals, Inc. Nucleic acid encoding 15571, a GPCR-like molecule of the secretin-like family
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
US6395877B1 (en) 1998-06-30 2002-05-28 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
EP1092024A2 (de) * 1998-06-30 2001-04-18 Millennium Pharmaceuticals, Inc. Rezeptor 14273, ein g-protein-gekoppelter rezeptor
US7534579B2 (en) 1998-06-30 2009-05-19 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
US6448005B1 (en) * 1998-06-30 2002-09-10 Millennium Pharmaceuticals, Inc. 14723 Receptor, a novel G-protein coupled receptor
AU6263999A (en) * 1998-09-28 2000-04-17 Chiron Corporation Human genes and gene expression products
EP1144625A2 (de) * 1999-01-29 2001-10-17 Incyte Pharmaceuticals, Inc. Nukleinsäure bindende proteine
EP1179000A4 (de) * 1999-02-26 2005-10-12 Millennium Pharm Inc Ausscheidungsproteine und ihre verwendung
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
AU4484400A (en) * 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
WO2001009317A1 (fr) * 1999-07-29 2001-02-08 Helix Research Institute Gene associe au cancer de l'estomac
CN1300845A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人二酰基甘油蛋白激酶亚单位9和编码这种多肽的多核苷酸
AU2153401A (en) * 1999-12-29 2001-07-16 Aros Applied Biotechnology Aps Gene expression in biological conditions
DE10004102A1 (de) * 2000-01-31 2002-06-20 Metagen Pharmaceuticals Gmbh Nachweis von differenzieller Genexpression
US20020102640A1 (en) * 2000-02-09 2002-08-01 Hubert Rene S. 83P5G4: a tissue specific protein highly expressed in prostate cancer
US6627423B2 (en) 2000-03-24 2003-09-30 Millennium Pharmaceuticals, Inc. 21481, a novel dehydrogenase molecule and uses therefor
US6511834B1 (en) 2000-03-24 2003-01-28 Millennium Pharmaceuticals, Inc. 32142,21481,25964,21686, novel human dehydrogenase molecules and uses therefor
WO2001072781A2 (en) * 2000-03-28 2001-10-04 Chiron Corporation Human genes and expression products
WO2002016614A1 (en) * 2000-08-18 2002-02-28 Merck Patent Gmbh Identification of a human n-terminal acetyltransferase gene
EP1326985A1 (de) * 2000-08-18 2003-07-16 MERCK PATENT GmbH Identifizierung eines menschlichen n-terminalen acetyltransferase-gens
JP2004535785A (ja) 2000-11-22 2004-12-02 ディアデクサス インコーポレーテッド 乳房特異的遺伝子およびタンパク質に関する組成物および方法
US7601825B2 (en) 2001-03-05 2009-10-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
DE10118452A1 (de) * 2001-04-12 2002-10-31 Joern Bullerdiek Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse
CA2432937A1 (en) * 2002-03-07 2003-09-07 Bf Research Institute, Inc. P18abrp gene and p18abrp protein, and novel gene/protein (p60trp) suppressing cell death and substances promoting cell death by interaction with the same
EP1426442A1 (de) * 2002-12-02 2004-06-09 MTM Laboratories AG Markermoleküle, die mit colorektalen Läsionen assoziiert sind
US7306910B2 (en) 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
ES2735531T3 (es) * 2005-08-23 2019-12-19 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP3501550A1 (de) 2012-04-02 2019-06-26 Moderna Therapeutics, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4349404A3 (de) 2015-10-22 2024-06-19 ModernaTX, Inc. Impfstoffe gegen respiratorische viren
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
EP3364950A4 (de) 2015-10-22 2019-10-23 ModernaTX, Inc. Impfstoffe gegen tropenkrankheiten
CN109563550A (zh) * 2016-08-04 2019-04-02 静冈县 判定有无癌症发病风险的方法
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
EP3582790A4 (de) 2017-02-16 2020-11-25 ModernaTX, Inc. Hochwirksame immunogene zusammensetzungen
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN112233741B (zh) * 2020-09-30 2024-03-01 吾征智能技术(北京)有限公司 一种基于聚类的文本分类系统、设备、存储介质

Also Published As

Publication number Publication date
EP1190058A2 (de) 2002-03-27
WO1999033982A3 (en) 1999-12-23
JP2002500010A (ja) 2002-01-08
WO1999033982A2 (en) 1999-07-08

Similar Documents

Publication Publication Date Title
AU2095599A (en) Human genes and gene expression products i
AU4187499A (en) Human genes and gene expression products v
AU4053699A (en) Novel human genes and gene expression products
AU6069300A (en) Novel human genes and gene expression products
AU2001285047A1 (en) Human genes and gene expression products
AU2001245619A1 (en) Human genes and gene expression products
AU5730896A (en) Fucosyltransferase genes and uses thereof
AUPP249298A0 (en) Synthetic genes and genetic constructs comprising same I
AU2820595A (en) Colon specific genes and proteins
AU2001249125A1 (en) Human fgf-23 gene and gene expression products
AU6418498A (en) Human genes
AU2809897A (en) Novel human cytomegalovirus dna constructs and uses therefor
AU2001245535A1 (en) Human fgf-23 gene and gene expression products
AU4803997A (en) Polymorphisms and new genes in the region of the human hemochromatosis gene
AU8536998A (en) Regulatory sequences involved in hypoxia regulated gene expression and uses thereof
AU8490998A (en) Glutenin genes and their uses
IL136826A0 (en) Essential bacterial genes and their use
AU4329300A (en) Human mesenchymal dnas and expression products
AU1101901A (en) Human fgf-20 gene and gene expression products
GB9708526D0 (en) Eukaryotic gene expression cassette and uses thereof
AU6263999A (en) Human genes and gene expression products
AU4862396A (en) Human obesity gene
AU3717797A (en) Method to co-detect introduced genes and their products
AU9131698A (en) Human genes regulated by human cytomegalovirus and interferon
AU3133799A (en) Seed-coat promoters, genes and gene products

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase